Lilly is paying $50 million as a "stalking horse" for Sangamo Therapeutics capsid delivery program, "zinc finger" gene-editing and modular integrase platforms and brain disease treatment.
Astellas is paying $50 million for the Fabry disease late-stage gene therapy program.
